<DOC>
	<DOC>NCT01137708</DOC>
	<brief_summary>This study is designed to assess whether co-administration of CP-690,550 and oral contraceptives will effect the metabolism of the oral contraceptives in healthy volunteers.</brief_summary>
	<brief_title>CP-690,550 And Oral Contraception Drug-Drug Interaction Study</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Healthy female subjects No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis Any medical reason which would contraindicate the administration of oral contraceptives Clinically significant infections within the past 3 months or history of febrile illness within 5 days Positive screening test for Hepatitis B surface antigen, anti Hepatitis C antibody, or human immunodeficiency virus Pregnant or nursing women, and women of childbearing potential who are unwilling or unable to use an acceptable method of nonhormonal contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>drug interactions</keyword>
	<keyword>CYP3A</keyword>
	<keyword>oral contraceptive</keyword>
	<keyword>anti-rheumatic agents</keyword>
</DOC>